Company Filing History:
Years Active: 2014
Title: Pierre Peronneau: Innovator in Tumoral Vascularization Detection
Introduction
Pierre Peronneau is a notable inventor based in Chateauneuf en Thymerais, France. He has made significant contributions to the medical field, particularly in the detection of tumoral vascularization. His innovative approach has the potential to enhance the understanding and treatment of tumors.
Latest Patents
Pierre Peronneau holds a patent for a "Method and system for quantification of tumoral vascularization." This patent describes a method and system that processes a test signal in the medical domain. The process involves acquiring an input digital signal F(t) as a function of time t in the form of two-dimensional data. This signal results from the excitation of a substance within a test substrate, which emits a signal in response to the excitation. The method includes modeling the input digital signal F(t) based on a pre-established model and possibly generating an output digital signal I(t) from this modeling. The modeling is based on a specific formula where coefficients are estimated from the two-dimensional data. This innovative method is directed towards detecting tumoral vascularization or tumoral angiogenesis in tumors.
Career Highlights
Pierre Peronneau is associated with the Institut Gustave Roussy, a leading cancer research center. His work at this institution has allowed him to focus on groundbreaking research in the field of oncology. His dedication to advancing medical technology is evident through his patent and ongoing research efforts.
Collaborations
Pierre has collaborated with notable colleagues, including Nicolas Elie and Nathalie Lassau. These collaborations have likely contributed to the development and refinement of his innovative methods in medical research.
Conclusion
Pierre Peronneau's contributions to the field of tumoral vascularization detection exemplify the impact of innovation in medicine. His patent and work at the Institut Gustave Roussy highlight his commitment to advancing cancer research and improving patient outcomes.